Transcode Therapeutics (RNAZ) Retained Earnings (2020 - 2026)

Transcode Therapeutics (RNAZ) has reported Retained Earnings for 7 consecutive years, with -$122.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings fell 242.8% year-over-year to -$122.4 million; the trailing twelve-month figure through Jun 2026 stood at -$122.4 million (down 242.8% YoY), and the FY2025 full-year result was $108.2 million, up 271.19% from the prior year.
• Retained Earnings declined to -$122.4 million in Q2 2026 per RNAZ's latest filing, from $116.9 million in the prior quarter.
• Across five years, Retained Earnings topped out at $116.9 million in Q1 2026 and bottomed at -$122.4 million in Q2 2026.
• Historically, Retained Earnings has averaged $38.4 million across 5 years, with a median of $47.4 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Retained Earnings surged 696.44% in 2022, then plunged 242.8% in 2026.
• Over 5 years, Retained Earnings stood at $31.1 million in 2022, then surged by 54.47% to $48.1 million in 2023, then sank by 231.51% to -$63.2 million in 2024, then soared by 271.19% to $108.2 million in 2025, then sank by 213.13% to -$122.4 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$122.4 million, $116.9 million, and $108.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.